Astellas' mAb against PSCA meets pancreatic cancer goal

Astellas Pharma Inc. (Tokyo:4503) said AGS-1C4D4 plus gemcitabine met the primary endpoint of significantly improving the survival rate at six months vs. gemcitabine alone in a Phase II trial to treat...